Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.19
+0.05 (0.35%)
At close: Dec 5, 2025, 4:00 PM EST
14.22
+0.03 (0.24%)
After-hours: Dec 5, 2025, 7:58 PM EST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 88.05B INR in the quarter ending September 30, 2025, with 9.84% growth. This brings the company's revenue in the last twelve months to 342.15B, up 14.10% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
342.15B INR
Revenue Growth
+14.10%
P/S Ratio
3.06
Revenue / Employee
12,302,650 INR
Employees
27,811
Market Cap
11.79B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RDY News
- 4 days ago - Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies - Business Wire
- 5 weeks ago - Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds - Seeking Alpha
- 6 weeks ago - Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 2 months ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 3 months ago - Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. - GlobeNewsWire
- 4 months ago - Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Dr. Reddy's Q1FY26 Financial Results - Business Wire
- 4 months ago - India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says - Reuters